Form 4 for LFCR LIFECORE BIOMEDICAL, INC. DE
Accepted 2024-07-10 00:00:00 ET · period of report 2024-07-08 · accession 0001628280-24-031634 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-10 | 2024-07-08 | LFCR | Calloway Nathaniel | Dir | A - Grant | — | +30.0K | 58.1K | +107% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-08 | A | A | 30,000 | — | 58,069 | D | — | — | (F1) The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. (F2) Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. |